Search Results

There are 9310 results for: content related to: Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

  1. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

    Movement Disorders

    Volume 21, Issue 3, March 2006, Pages: 343–353, Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer and Johannes Schwarz

    Version of Record online : 6 OCT 2005, DOI: 10.1002/mds.20724

  2. A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease

    European Journal of Neurology

    Volume 4, Issue 6, November 1997, Pages: 537–543, V. Nohria and A. Partiot

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1997.tb00403.x

  3. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study

    Movement Disorders

    Volume 9, Issue 4, 1994, Pages: 431–436, Dr. G. Pezzoli, E. Martignoni, C. Pacchetti, V. A. Angeleri, P. Lamberti, A. Muratorio, U. Bonuccelli, M. De Mari, N. Foschi, E. Cossutta, F. Nicoletti, F. Giammona, M. Canesi, G. Scarlato, T. Caraceni and E. Moscarelli

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870090409

  4. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, crossover study

    European Journal of Neurology

    Volume 3, Issue 1, January 1996, Pages: 44–49, J. Boas, J. Worm-Petersen, E. Dupont, B. Mikkelsen and L Wermuth

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1996.tb00188.x

  5. Pergolide, a potent long-acting dopamine-receptor agonist

    Clinical Pharmacology & Therapeutics

    Volume 27, Issue 5, May 1980, Pages: 642–651, Louis Lemberger, Ross Crabtree and J Thomas Callaghan

    Version of Record online : 11 MAY 1980, DOI: 10.1038/clpt.1980.91

  6. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Version of Record online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  7. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

    Movement Disorders

    Volume 9, Issue 1, 1994, Pages: 40–47, Dr. C. W. Olanow, S. Fahn, M. Muenter, H. Klawans, H. Hurtig, M. Stern, I. Shoulson, R. Kurlan, J. D. Grimes, J. Jankovic, M. Hoehn, C. H. Markham, R. Duvisin, O. Reinmuth, H. A. Leonard, E. Ahlskog, R. Feldman, L. Hershey and M. D. Yahr

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870090107

  8. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004553.pub2

  9. Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleic-related enzymes in mouse brain

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 2, April 2014, Pages: 217–220, Katsuhito Nagai and Hiroki Konishi

    Version of Record online : 7 NOV 2012, DOI: 10.1111/fcp.12011

  10. DA agonists - Ergot derivaties: Pergolide

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S79–S82,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5566

  11. Physiologic disposition of pergolide

    Clinical Pharmacology & Therapeutics

    Volume 30, Issue 2, August 1981, Pages: 258–265, Alan Rubin, Louis Lemberger and Patricia Dhahir

    Version of Record online : 25 AUG 1981, DOI: 10.1038/clpt.1981.157


    Clinical Endocrinology

    Volume 22, Issue 5, May 1985, Pages: 611–616, A. GROSSMAN, P-M. G. BOULOUX, R. LONERAGAN, LESLEY H. REES, J. A. H. WASS and G. M. BESSER

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1985.tb02996.x

  13. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

    Movement Disorders

    Volume 10, Issue 5, September 1995, Pages: 668–671, Dr. A. M. Bonnet, I. Serre, R. Marconi, Y. Agid and B. Dubois

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870100522

  14. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

    Movement Disorders

    Volume 14, Issue 6, November 1999, Pages: 940–946, J. Eric Ahlskog, Ryan J. Uitti, Michael K. O'Connor, Demetrius M. Maraganore, Joseph Y. Matsumoto, Kathy F. Stark, Margaret F. Turk and Omer L. Burnett

    Version of Record online : 25 JAN 2001, DOI: 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y

  15. Case series of equine pituitary pars intermedia dysfunction in a tropical climate

    Australian Veterinary Journal

    Volume 90, Issue 11, November 2012, Pages: 451–456, CW Spelta and JE Axon

    Version of Record online : 11 OCT 2012, DOI: 10.1111/j.1751-0813.2012.00997.x

  16. Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone

    Journal of Pharmaceutical Sciences

    Volume 72, Issue 7, July 1983, Pages: 733–736, Robert V. Smith, Patrick J. Davis and Kathleen M. Kerr

    Version of Record online : 16 SEP 2006, DOI: 10.1002/jps.2600720704

  17. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses

    Veterinary Dermatology

    Volume 24, Issue 1, February 2013, Pages: 212–e47, Marie Innerå, Annette D. Petersen, Danielle R. Desjardins, Barbara A. Steficek, Edmund J. Rosser Jr and Harold C. Schott II

    Version of Record online : 19 JAN 2013, DOI: 10.1111/j.1365-3164.2012.01080.x

  18. Bromocriptine use and the risk of valvular heart disease

    Movement Disorders

    Volume 24, Issue 3, 15 February 2009, Pages: 344–349, Louis C.S. Tan, Kenneth K.C. Ng, Wing-Lok Au, Raymond K.K. Lee, Yiong-Huak Chan and Nigel C.K. Tan

    Version of Record online : 6 NOV 2008, DOI: 10.1002/mds.22228

  19. The dopamine-γ aminobutyric acid interaction in the striatum of the rat is differently regulated by dopamine D-1 and D-2 types of receptor: evidence obtained with rotational behavioural experiments

    Acta Physiologica Scandinavica

    Volume 129, Issue 3, March 1987, Pages: 371–380, M. HERRERA-MARSCHITZ and U. UNGERSTEDT

    Version of Record online : 8 DEC 2008, DOI: 10.1111/j.1748-1716.1987.tb08080.x

  20. Development of selective dopamine receptor agonists as novel cardiovascular drugs

    Drug Development Research

    Volume 4, Issue 3, 1984, Pages: 285–300, Dr. Richard A. Hahn

    Version of Record online : 5 OCT 2004, DOI: 10.1002/ddr.430040306